NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
Go back to NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH| Vanguard Minerals Corporation (NASDAQ: NGM) | Delayed: 1.54 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.54 | 52 Week High | $0.53 | |||
| Open | $105.70 | 52 Week Low | $0.39 | |||
| Day High | $1.54 | P/E | N/A | |||
| Day Low | $1.54 | EPS | $0.00 | |||
| Volume | 840,001 | |||||
